AbbVie partners with IPO-bound Iambic as Insilico picks another AI-designed obesity drug candidate

Sep 28, 2026 · Issue 9 · 3 sources, 3 articles

AbbVie is working with IPO-bound Iambic on AI-led drug discovery. Insilico has chosen an AI-designed GIPR blocker as its next obesity drug candidate.

Who is affected and how

pharmaceuticals

AI-led research partnerships and AI-designed candidates are also appearing in large companies' portfolios.

Sources

• AbbVie partners with IPO-bound Iambic for AI-led drug discoveriescrain's chicago business · Sep 28, 2026
• Insilico picks AI-designed GIPR blocker for next obesity druglongevity.technology · Oct 2, 2026
• Insilico Medicine nominates AI-designed GIPR antagonist ISM1354 for obesity and metabolic disease | Drug Target Reviewdrugtargetreview.com · Oct 2, 2026

Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.